English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

We present the analysis of a prospective multicentre study to investigate genetic effects on the prognosis of newly treated epilepsy. Patients with a new clinical diagnosis of epilepsy requiring medication were recruited and followed up prospectively. The clinical outcome was defined as freedom from seizures for a minimum of 12 months in accordance with the consensus statement from the International League Against Epilepsy (ILAE). Genetic effects on remission of seizures after starting treatment were analysed with and without adjustment for significant clinical prognostic factors, and the results from each cohort were combined using a fixed-effects meta-analysis. After quality control (QC), we analysed 889 newly treated epilepsy patients using 472 450 genotyped and 6.9 × 10 6  imputed single-nucleotide polymorphisms. Suggestive evidence for association (defined as  P  meta  &lt; 5.0 × 10 −7 ) with remission of seizures after starting treatment was observed at three loci: 6p12.2 (rs492146,  P  meta  = 2.1 × 10 −7 , OR[G] = 0.57), 9p23 (rs72700966,  P  meta  = 3.1 × 10 −7 , OR[C] = 2.70) and 15q13.2 (rs143536437,  P  meta  = 3.2 × 10 −7 , OR[C] = 1.92). Genes of biological interest at these loci include  PTPRD  and  ARHGAP11B  (encoding functions implicated in neuronal development) and  GSTA4  (a phase II biotransformation enzyme). Pathway analysis using two independent methods implicated a number of pathways in the prognosis of epilepsy, including KEGG categories ‘calcium signaling pathway’ and ‘phosphatidylinositol signaling pathway’. Through a series of power curves, we conclude that it is unlikely any single common variant explains &gt;4.4% of the variation in the outcome of newly treated epilepsy.

A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy